Peanut oral immunotherapy protects patients from accidental allergic reactions to peanut

Trendelenburg, Valérie; Blümchen, Katharina; Bellach, Johanna; Ahrens, Frank; Gruebl, Armin; Hamelmann, Eckard; Hansen, Gesine; Heinzmann, Andrea; Nemat, Katja; Holzhauser, Thomas; Röder, Martin; Niggemann, B.; Beyer, Kirsten

doi:10.1016/j.jaip.2020.03.043

Cited by 28 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, in the historical control group, one child experienced anaphylaxis, while no children in the LOIT group experienced anaphylaxis. It has also been previously reported that peanut OIT had significantly prevented accidental allergic reactions in the OIT group compared with the placebo group 23. Therefore, LOIT might have prevented anaphylactic symptoms induced through accidental ingestions.F I G U R E 2Changes in sIgE levels between the baseline and after 3 y.…”

mentioning

confidence: 61%

Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow’s milk allergy

Miura

Nagakura

Nishino

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Cow's milk (CM) allergy, one of the major food allergies with a prevalence of 2%-3%, 1,2 accounts for 21% of food-induced anaphylaxis in the UK. 3 In Japan, CM is the second most common cause of food allergy in children. Although about 50%-90% of children with childhood-onset CM allergy acquire tolerance by school age, 4,5 children with severe CM allergy that have high CM-specific immunoglobulin E (sIgE) levels and a history of anaphylaxis often have persistent CM allergy. 4,6

show abstract

mentioning

confidence: 61%

Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow’s milk allergy

Miura

Nagakura

Nishino

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…Only 1 reaction (12.5%) in the active group versus 10 (42%) in the placebo group was graded as severe, and the 1 in the active group was when the subject was early in the build-up phase (4.5-mg dose). 59 Higher levels of desensitization have been achieved in other studies and the 2 community practice reports. 2,15,16 Sustaining these higher doses long-term can be complicated by nonadherence due to adverse effects or issues with taste.…”

Section: Maintenance Dosementioning

confidence: 75%

Integrating oral immunotherapy into clinical practice

Leonard

Laubach

Wang

2021

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Access to OFCs before starting OIT, to ensure that only those who are truly allergic undergo OIT, may not be possible under pandemic ambulatory care constraints. 34 …”

Section: Oit During Covid-19mentioning

confidence: 99%

“… 40 This is further supported by sublingual immunotherapy and low-dose OIT studies that demonstrated acceptable safety and reduction in accidental reactions, even at low doses. 34 , 41 Patients need to be reminded that the final OIT dose is likely not the most important determinant of success, but rather that each dose contributes to building tolerance, irrespective of the time taken to reach the predetermined target. Although there has been no direct comparison of standard versus slower buildup approaches, the incorporation of slower approaches to OIT updosing in select patients may be considered even after this pandemic.…”

Section: Oit During Covid-19mentioning

confidence: 99%

Novel Approaches to Food Allergy Management During COVID-19 Inspire Long-Term Change

Mack

Chan

Shaker

et al. 2020

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

The SARS-CoV2 pandemic has prompted a re-evaluation of our current practice of medicine. The seemingly abrupt worldwide spread of this disease resulted in immediate changes and a reduction in many allergy-focussed services and procedures. The reality of the long-term circulation of this virus in our communities requires us to evolve as a specialty. In this article, we outline current and future challenges in the management of food allergy in light of coronavirus disease 2019 (COVID-19). We focus on infant food allergy prevention, management of anaphylaxis, accurate diagnosis with oral food challenges, and active management of food allergy with oral immunotherapy. This article identifies the challenges of conflicting guidelines, shortcomings of acute management approaches, and inherent system deficiencies. We offer perspectives and strategies that can be implemented now, including an evaluation of virtual care and telemedicine for the management of food allergy. The use of a shared decision-making model results in novel approaches that can benefit our patients and our specialty for years to come. COVID-19 has forced us to re-evaluate our current way of thinking about food allergy management to better treat our patients.

show abstract

Peanut oral immunotherapy protects patients from accidental allergic reactions to peanut

Cited by 28 publications

References 8 publications

Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow’s milk allergy

Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow’s milk allergy

Integrating oral immunotherapy into clinical practice

Novel Approaches to Food Allergy Management During COVID-19 Inspire Long-Term Change

Contact Info

Product

Resources

About